1. Home
  2. AGEN vs INVE Comparison

AGEN vs INVE Comparison

Compare AGEN & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGEN
  • INVE
  • Stock Information
  • Founded
  • AGEN 1994
  • INVE 1990
  • Country
  • AGEN United States
  • INVE United States
  • Employees
  • AGEN N/A
  • INVE N/A
  • Industry
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • INVE Computer peripheral equipment
  • Sector
  • AGEN Health Care
  • INVE Technology
  • Exchange
  • AGEN Nasdaq
  • INVE Nasdaq
  • Market Cap
  • AGEN 87.7M
  • INVE 82.7M
  • IPO Year
  • AGEN 2000
  • INVE 1997
  • Fundamental
  • Price
  • AGEN $5.29
  • INVE $3.58
  • Analyst Decision
  • AGEN Strong Buy
  • INVE Strong Buy
  • Analyst Count
  • AGEN 3
  • INVE 3
  • Target Price
  • AGEN $16.33
  • INVE $6.50
  • AVG Volume (30 Days)
  • AGEN 1.2M
  • INVE 76.3K
  • Earning Date
  • AGEN 08-11-2025
  • INVE 08-07-2025
  • Dividend Yield
  • AGEN N/A
  • INVE N/A
  • EPS Growth
  • AGEN N/A
  • INVE N/A
  • EPS
  • AGEN N/A
  • INVE 3.12
  • Revenue
  • AGEN $99,524,000.00
  • INVE $25,239,000.00
  • Revenue This Year
  • AGEN $25.31
  • INVE N/A
  • Revenue Next Year
  • AGEN N/A
  • INVE $9.00
  • P/E Ratio
  • AGEN N/A
  • INVE $1.16
  • Revenue Growth
  • AGEN N/A
  • INVE N/A
  • 52 Week Low
  • AGEN $1.38
  • INVE $2.86
  • 52 Week High
  • AGEN $7.34
  • INVE $4.29
  • Technical
  • Relative Strength Index (RSI)
  • AGEN 44.92
  • INVE 54.48
  • Support Level
  • AGEN $5.34
  • INVE $3.37
  • Resistance Level
  • AGEN $6.58
  • INVE $3.64
  • Average True Range (ATR)
  • AGEN 0.44
  • INVE 0.20
  • MACD
  • AGEN -0.16
  • INVE -0.02
  • Stochastic Oscillator
  • AGEN 10.69
  • INVE 46.60

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.

Share on Social Networks: